Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
DYN 
Dyne Therapeutics Inc (DYN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: DYN (3-star) is a STRONG-BUY. BUY since 42 days. Simulated Profits (51.23%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $36.94
1 Year Target Price $36.94
| 7 | Strong Buy |
| 6 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 220.15% | Avg. Invested days 49 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.63B USD | Price to earnings Ratio - | 1Y Target Price 36.94 |
Price to earnings Ratio - | 1Y Target Price 36.94 | ||
Volume (30-day avg) 14 | Beta 1.3 | 52 Weeks Range 6.36 - 28.96 | Updated Date 12/9/2025 |
52 Weeks Range 6.36 - 28.96 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.32% | Return on Equity (TTM) -60.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2497858804 | Price to Sales(TTM) - |
Enterprise Value 2497858804 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.87 | Shares Outstanding 142824687 | Shares Floating 132886945 |
Shares Outstanding 142824687 | Shares Floating 132886945 | ||
Percent Insiders 0.5 | Percent Institutions 111.23 |
Upturn AI SWOT
Dyne Therapeutics Inc
Company Overview
History and Background
Dyne Therapeutics, Inc. was founded in 2017 and is a biotechnology company focused on discovering and developing targeted gene therapies for rare genetic diseases. The company has rapidly advanced its pipeline, leveraging its proprietary FORCEu2122 delivery platform to address unmet medical needs.
Core Business Areas
- Rare Genetic Diseases: Dyne Therapeutics is dedicated to developing gene therapies for a range of rare genetic diseases, with a particular focus on muscle and liver disorders. Their approach aims to provide durable, one-time treatments by delivering therapeutic genes to target tissues.
Leadership and Structure
Dyne Therapeutics is led by a management team with extensive experience in biotechnology and drug development. The company operates as a publicly traded entity with a standard corporate governance structure.
Top Products and Market Share
Key Offerings
- Dyne Therapeutics Pipeline: Dyne Therapeutics is in the preclinical and early clinical stages of development for several gene therapies. Their lead programs target Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and other rare genetic muscle and liver diseases. Specific product candidates are designated by their target disease (e.g., DYNE-101 for DM1, DYNE-201 for DMD). As these are investigational therapies, market share data is not yet applicable. Competitors in these therapeutic areas include other gene therapy developers and traditional pharmaceutical companies working on treatments for these rare diseases.
Market Dynamics
Industry Overview
The gene therapy market is a rapidly evolving and high-growth sector within the biotechnology and pharmaceutical industries. It is characterized by significant scientific innovation, substantial investment, and the potential for transformative treatments for previously intractable diseases. The industry faces challenges related to manufacturing scalability, regulatory pathways, and high treatment costs.
Positioning
Dyne Therapeutics is positioned as an emerging player in the gene therapy space, focusing on rare neuromuscular and liver diseases. Its proprietary FORCEu2122 delivery platform is a key competitive advantage, designed for efficient and targeted delivery of gene therapies.
Total Addressable Market (TAM)
The TAM for rare genetic diseases, particularly neuromuscular and liver disorders, is substantial and growing as diagnostic capabilities improve and novel therapies become available. Dyne Therapeutics aims to capture a significant portion of the TAM for the specific rare diseases it targets, many of which currently lack effective treatments.
Upturn SWOT Analysis
Strengths
- Proprietary FORCEu2122 delivery platform designed for targeted gene delivery.
- Focus on a growing and unmet medical need in rare genetic diseases.
- Experienced management team with a strong track record in biotech.
- Advancing pipeline with programs in early clinical development.
Weaknesses
- Early-stage of drug development, with no approved products yet.
- High risk associated with gene therapy development.
- Dependence on successful clinical trial outcomes.
- Potential manufacturing and scalability challenges for gene therapies.
Opportunities
- Significant unmet medical needs in target rare disease indications.
- Potential for first-in-class or best-in-class therapies.
- Partnership and collaboration opportunities with larger pharmaceutical companies.
- Advancements in gene editing and delivery technologies.
Threats
- Clinical trial failures or setbacks.
- Intense competition from other gene therapy developers.
- Regulatory hurdles and evolving approval pathways.
- High cost of development and potential pricing challenges for approved therapies.
Competitors and Market Share
Key Competitors
- Sarepta Therapeutics (SRPT)
- Pfizer Inc. (PFE)
- Novartis AG (NVS)
Competitive Landscape
Dyne Therapeutics faces competition from established pharmaceutical giants and other specialized gene therapy companies. Its competitive advantages lie in its proprietary delivery platform and focused approach to specific rare diseases. However, competitors may have larger resources, more established manufacturing capabilities, and broader portfolios.
Growth Trajectory and Initiatives
Historical Growth: Dyne Therapeutics has experienced rapid growth in its operational scale since its inception, marked by significant investment in its research platform and pipeline advancement. This growth is characterized by increasing R&D expenditure and team expansion.
Future Projections: Future growth projections for Dyne Therapeutics are heavily dependent on the successful progression of its gene therapy candidates through clinical trials and subsequent regulatory approvals. Analyst expectations are generally tied to clinical milestones and potential market penetration upon approval.
Recent Initiatives: Recent initiatives likely include the advancement of its lead programs into clinical trials, expansion of its manufacturing capabilities, and potential strategic partnerships or collaborations to further its development efforts.
Summary
Dyne Therapeutics is an innovative gene therapy company targeting rare genetic diseases with promising early-stage pipeline. Its strengths lie in its proprietary delivery platform and focus on unmet medical needs, while its primary weaknesses stem from the inherent risks and long timelines of drug development. The company has significant opportunities in a growing market but faces threats from clinical trial failures and intense competition. Continued successful execution of its R&D strategy and securing adequate funding will be critical for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations
- Financial News Outlets
- Biotechnology Industry Analysis Reports
- Market Research Data
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risk, and investors should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions. Market share data for early-stage companies is often estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyne Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-17 | CEO, President & Director Mr. John G. Cox M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 240 | Website https://www.dyne-tx.com |
Full time employees 240 | Website https://www.dyne-tx.com | ||
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.